[3]
Liu, D.X.; Liang, J.Q.; Fung, T.S. Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). In: Encyclopedia of Virology; Bamford, D.; Zuckerman, M., Eds.; Elsevier Science: Amsterdam, 2021; Vol. 4, pp. 428-440.
[14]
Muniyappa, R.; Gubbi, S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am. J. Physiol. Endocrinol. Metab., 2020, 318(5), E736-E41.
[18]
Feng, Z.; Diao, B.; Wang, R.; Wang, G.; Wang, C.; Tan, Y. The novel severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) directly decimates human spleens and lymph nodes medRxiv, 2020, 2020
[30]
Liu, Q.; Zhu, Y.; Yong, W.K.; Sze, N.S.; Tan, N.S.; Ding, J.L. Cutting edge: Synchronization of IRF1, JunB, and C/EBPβ activities during TLR3-TLR7 cross-talk orchestrates timely cytokine synergy in the proinflammatory response J. Immunol.(Baltimore), 2015, 195(3), 801-805.
[50]
Long, Q-X.; Liu, B-Z.; Deng, H-J.; Wu, G-C.; Deng, K.; Chen, Y-K.; Liao, P.; Qiu, J.F.; Lin, Y.; Cai, X.F.; Wang, D.Q.; Hu, Y.; Ren, J.H.; Tang, N.; Xu, Y.Y.; Yu, L.H.; Mo, Z.; Gong, F.; Zhang, X.L.; Tian, W.G.; Hu, L.; Zhang, X.X.; Xiang, J.L.; Du, H.X.; Liu, H.W.; Lang, C.H.; Luo, X.H.; Wu, S.B.; Cui, X.P.; Zhou, Z.; Zhu, M.M.; Wang, J.; Xue, C.J.; Li, X.F.; Wang, L.; Li, Z.J.; Wang, K.; Niu, C.C.; Yang, Q.J.; Tang, X.J.; Zhang, Y.; Liu, X.M.; Li, J.J.; Zhang, D.C.; Zhang, F.; Liu, P.; Yuan, J.; Li, Q.; Hu, J.L.; Chen, J.; Huang, A.L. Antibody responses to SARS-CoV-2 in patients with COVID-19.
Nat. Med., 2020,
26(6), 845-848.
[
http://dx.doi.org/10.1038/s41591-020-0897-1] [PMID:
32350462]
[58]
Wu, D.; Yang, X.O. TH17 responses in cytokine storm of COVID- 19: An emerging target of JAK2 inhibitor Fedratinib J. Microbiol. Immunol. Infect., 2020, 53(3), 368-370.
[69]
Kaklamanos, A.; Belogiannis, K.; Skendros, P.; Gorgoulis, V.G.; Vlachoyiannopoulos, P.G.; Tzioufas, A.G. COVID-19 immunobiology: Lessons learned, new questions arise Front. Immunol., 2021, 12, 719023.
[76]
Yu, L.; Tong, Y.; Shen, G.; Fu, A.; Lai, Y.; Zhou, X.; Yuan, Y.; Wang, Y.; Pan, Y.; Yu, Z.; Li, Y.; Liu, T.; Jiang, H. Immunodepletion with hypoxemia: A potential high risk subtype of coronavirus disease medRxiv, 2020.
[81]
Diao, B.; Wang, C.; Tan, Y.; Chen, X.; Liu, Y.; Ning, L.; Chen, L.; Li, M.; Liu, Y.; Wang, G.; Yuan, Z.; Feng, Z.; Zhang, Y.; Wu, Y.; Chen, Y. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Front. Immunol., 2020, 11, 827.
[91]
Shah, V.K.; Firmal, P.; Alam, A.; Ganguly, D.; Chattopadhyay, S. Overview of immune response during SARS-CoV-2 infection Lessons From the Past., 1949, 2020, 11.
[92]
Yang, J.; Zheng, Y.; Gou, X.; Pu, K.; Chen, Z.; Guo, Q. Prevalence of comorbidities and its effects in patients infected with SARSCoV- 2: A systematic review and meta-analysis Int. J. Infect. Dis., 2020, 94, 91-95.
[101]
Griesbeck, M.; Ziegler, S.; Laffont, S.; Smith, N.; Chauveau, L.; Tomezsko, P. Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-α production in women J. Immunol., 2015, 195(11), 5327-5336.
[114]
Qin, W.; Chen, S.; Zhang, Y.; Dong, F.; Zhang, Z.; Hu, B. Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at three-month follow-up Eur. Respir. J., 2021, 58(1), 2003677.
[116]
Salamanna, F.; Veronesi, F.; Martini, L.; Landini, M.P.; Fini, M. Post-COVID-19 syndrome: The persistent symptoms at the postviral stage of the disease. A systematic review of the current data. Front. Med. (Lausanne), 2021, 8, 653516.
[118]
Alonso-Bellido, I.M.; Bachiller, S.; Vázquez, G.; Cruz-Hernández, L.; Martínez, E.; Ruiz-Mateos, E. The other side of SARS-CoV-2 infection: Neurological sequelae in patients. Front. Aging Neurosci., 2021, 13(159)
[119]
Al-Jahdhami, I.; Al-Naamani, K.; Al-Mawali, A. The post-acute COVID-19 syndrome (long COVID) Oman Med. J., 2021, 36(1), e220.
[122]
Korompoki, E.; Gavriatopoulou, M.; Hicklen, R.S.; Ntanasis-Stathopoulos, I.; Kastritis, E.; Fotiou, D. Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J. Infect, 2021. S0163-4453(21), 00247-4.
[128]
Arashkia, A.; Jalilvand, S.; Mohajel, N.; Afchangi, A.; Azadmanesh, K.; Salehi-Vaziri, M. Severe acute respiratory syndromecoronavirus- 2 spike (S) protein based vaccine candidates: State of the art and future prospects Rev. Med. Virol., 2021, 31(3), e2183.
[131]
Corbett, K.S.; Edwards, D.K.; Leist, S.R.; Abiona, O.M.; Boyoglu-Barnum, S.; Gillespie, R.A.; Himansu, S.; Schäfer, A.; Ziwawo, C.T.; DiPiazza, A.T.; Dinnon, K.H.; Elbashir, S.M.; Shaw, C.A.; Woods, A.; Fritch, E.J.; Martinez, D.R.; Bock, K.W.; Minai, M.; Nagata, B.M.; Hutchinson, G.B.; Wu, K.; Henry, C.; Bahl, K.; Garcia-Dominguez, D.; Ma, L.; Renzi, I.; Kong, W.P.; Schmidt, S.D.; Wang, L.; Zhang, Y.; Phung, E.; Chang, L.A.; Loomis, R.J.; Altaras, N.E.; Narayanan, E.; Metkar, M.; Presnyak, V.; Liu, C.; Louder, M.K.; Shi, W.; Leung, K.; Yang, E.S.; West, A.; Gully, K.L.; Stevens, L.J.; Wang, N.; Wrapp, D.; Doria-Rose, N.A.; Stewart-Jones, G.; Bennett, H.; Alvarado, G.S.; Nason, M.C.; Ruckwardt, T.J.; McLellan, J.S.; Denison, M.R.; Chappell, J.D.; Moore, I.N.; Morabito, K.M.; Mascola, J.R.; Baric, R.S.; Carfi, A.; Graham, B.S. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Nature, 2020,
586(7830), 567-571.
[
http://dx.doi.org/10.1038/s41586-020-2622-0] [PMID:
32756549]
[147]
Han, B.; Song, Y.; Li, C.; Yang, W.; Ma, Q.; Jiang, Z.; Li, M.; Lian, X.; Jiao, W.; Wang, L.; Shu, Q.; Wu, Z.; Zhao, Y.; Li, Q.; Gao, Q. Safety, tolerability and immunogenicity of an inactivated SARS-CoV-2 Vaccine (CoronaVac) in healthy children and adolescents: A randomised, double-blind, and placebo-controlled, phase 1/2 clinical trial Lancet Infect. Dis., 2021, 21(12), 1645-1653.
[151]
Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; Bibi, S.; Briner, C.; Cicconi, P.; Collins, A.M.; Colin-Jones, R.; Cutland, C.L.; Darton, T.C.; Dheda, K.; Duncan, C.J.A.; Emary, K.R.W.; Ewer, K.J.; Fairlie, L.; Faust, S.N.; Feng, S.; Ferreira, D.M.; Finn, A.; Goodman, A.L.; Green, C.M.; Green, C.A.; Heath, P.T.; Hill, C.; Hill, H.; Hirsch, I.; Hodgson, S.H.C.; Izu, A.; Jackson, S.; Jenkin, D.; Joe, C.C.D.; Kerridge, S.; Koen, A.; Kwatra, G.; Lazarus, R.; Lawrie, A.M.; Lelliott, A.; Libri, V.; Lillie, P.J.; Mallory, R.; Mendes, A.V.A.; Milan, E.P.; Minassian, A.M.; McGregor, A.; Morrison, H.; Mujadidi, Y.F.; Nana, A.; O’Reilly, P.J.; Padayachee, S.D.; Pittella, A.; Plested, E.; Pollock, K.M.; Ramasamy, M.N.; Rhead, S.; Schwarzbold, A.V.; Singh, N.; Smith, A.; Song, R.; Snape, M.D.; Sprinz, E.; Sutherland, R.K.; Tarrant, R.; Thomson, E.C.; Török, M.E.; Toshner, M.; Turner, D.P.J.; Vekemans, J.; Villafana, T.L.; Watson, M.E.E.; Williams, C.J.; Douglas, A.D.; Hill, A.V.S.; Lambe, T.; Gilbert, S.C.; Pollard, A.J. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet, 2021,
397(10269), 99-111.
[
http://dx.doi.org/10.1016/S0140-6736(20)32661-1] [PMID:
33306989]
[153]
Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; Aley, P.K.; Angus, B.; Babbage, G.; Belij-Rammerstorfer, S.; Berry, L.; Bibi, S.; Bittaye, M.; Cathie, K.; Chappell, H.; Charlton, S.; Cicconi, P.; Clutterbuck, E.A.; Colin-Jones, R.; Dold, C.; Emary, K.R.W.; Fedosyuk, S.; Fuskova, M.; Gbesemete, D.; Green, C.; Hallis, B.; Hou, M.M.; Jenkin, D.; Joe, C.C.D.; Kelly, E.J.; Kerridge, S.; Lawrie, A.M.; Lelliott, A.; Lwin, M.N.; Makinson, R.; Marchevsky, N.G.; Mujadidi, Y.; Munro, A.P.S.; Pacurar, M.; Plested, E.; Rand, J.; Rawlinson, T.; Rhead, S.; Robinson, H.; Ritchie, A.J.; Ross-Russell, A.L.; Saich, S.; Singh, N.; Smith, C.C.; Snape, M.D.; Song, R.; Tarrant, R.; Themistocleous, Y.; Thomas, K.M.; Villafana, T.L.; Warren, S.C.; Watson, M.E.E.; Douglas, A.D.; Hill, A.V.S.; Lambe, T.; Gilbert, S.C.; Faust, S.N.; Pollard, A.J. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial.
Lancet, 2021,
396(10267), 1979-1993.
[
http://dx.doi.org/10.1016/S0140-6736(20)32466-1] [PMID:
33220855]
[156]
Teo, S.P. Review of COVID-19 vaccines and their evidence in older adults Ann. Geriatr. Med. Res., 2021, 25(1), 4-9.
[158]
Wu, Z.; Hu, Y.; Xu, M.; Chen, Z.; Yang, W.; Jiang, Z.; Li, M.; Jin, H.; Cui, G.; Chen, P.; Wang, L.; Zhao, G.; Ding, Y.; Zhao, Y.; Yin, W. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Lancet Infect. Dis., 2021, 21(6), 803-812.
Download PDF Flyer